A phase I study of recombinant human arginase I (rhArgI) for patients with advanced hepatocellular carcinoma.

被引：3
|
作者：
Yau, C. C.
Chan, P.
Pang, R.
Chan, W.
Cheng, P. N.
Poon, R.
机构：
[1] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China
[2] 813 Med Ctr Ltd, Hong Kong, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e13503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13503
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma
    Ooka, Yoshihiko
    Chiba, Tetsuhiro
    Ogasawara, Sadahisa
    Arai, Kuniaki
    Suzuki, Eiichiro
    Tawada, Akinobu
    Yamashita, Tatsuya
    Kanai, Fumihiko
    Kaneko, Shuichi
    Yokosuka, Osamu
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) : 723 - 728
  • [32] Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
    Furuse, J.
    Ishii, H.
    Nakajima, K.
    Nakachi, K.
    Suzuki, E.
    Yoshino, M.
    EJC SUPPLEMENTS, 2006, 4 (12): : 114 - 114
  • [33] Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
    Furuse, Junji
    Ishii, Hiroshi
    Nakachi, Kohei
    Suzuki, Eiichiro
    Shimizu, Satoshi
    Nakajima, Keiko
    CANCER SCIENCE, 2008, 99 (01) : 159 - 165
  • [34] Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.
    Yoo, Changhoon
    Kang, Jihoon
    Kim, Kyu-Pyo
    Lim, Ho Yeong
    Kim, Jee Hyun
    Lee, Myung Ah
    Kim, Tae-You
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] Characteristics and outcomes of patients with advanced hepatocellular carcinoma treated on phase I trials
    Subbiah, Ishwaria Mohan
    Janku, Filip
    Tsimberidou, Apostolia Maria
    Naing, Aung
    Kaseb, Ahmed Omar
    Hong, David S.
    Subbiah, Vivek
    Hess, Kenneth R.
    Akmal, Owais
    Falchook, Gerald Steven
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [36] Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma
    Yau, Thomas
    Cheng, Paul N.
    Chan, Pierre
    Chen, Li
    Yuen, Jimmy
    Pang, Roberta
    Fan, Sheung Tat
    Wheatley, Denys N.
    Poon, Ronnie T.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (02) : 496 - 504
  • [37] PHASE-I STUDY OF RECOMBINANT HUMAN INTERFERON-BETA IN PATIENTS WITH ADVANCED CANCER
    HU, E
    HORNING, SJ
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1987, 6 (02): : 121 - 129
  • [38] Preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and quality of life study of pegylated recombinant human arginase 1 in patients with advanced hepatocellular carcinoma
    Thomas Yau
    Paul N. Cheng
    Pierre Chan
    Li Chen
    Jimmy Yuen
    Roberta Pang
    Sheung Tat Fan
    Denys N. Wheatley
    Ronnie T. Poon
    Investigational New Drugs, 2015, 33 : 496 - 504
  • [39] Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors
    Thomas, JP
    Arzoomanian, RZ
    Alberti, D
    Marnocha, R
    Lee, F
    Friedl, A
    Tutsch, K
    Dresen, A
    Geiger, P
    Pluda, J
    Fogler, W
    Schiller, JH
    Wilding, G
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) : 223 - 231
  • [40] A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta L.
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345